Good find ..... well, what if we just sit back on our hands, and wait for BP and other companies to show us how to raise cash and how to get it done? ..... and then when the industry decides it is epigenetics' time, BP's are scrambling and tripping over themselves to buy RVX and get in the game also with competitive solutions?  

This study you reference may (or may not) be epigenetics based, but there will be competitive companies wanting entrants into the various disease entities. At some point. Especially if they have threatened or waning revenues to protect/grow. Big public companies live and die for Qtr over Qtr and YOY growth, or heads roll. At some point, the risk of a strategic purchase is less worrisome than a slow and gradual malaise and predicatable revenues decline. Hoping anyway! Also, hoping I am still top side if/when it occurs lol ...